Abstract
Sarcomas are a group of rare malignant neoplasms of mesenchymal origin which may occur in skeletal and extraskeletal tissue, including muscles, tendons, fat, synovium, fibrous tissue, blood vessels and the peripheral nervous system [1, 2]. Tumours of soft tissue and bone are characterised by a high degree of morphological, molecular and clinical heterogeneity. Sarcomas are classified by the World Health Organization (WHO) according to histological features into over 100 types, of which at least 70% are soft tissue sarcomas [2, 3]. The classification system for sarcomas is an evolving process, reflecting the advent of novel molecular, cytogenetic and immunohistochemical techniques which facilitate the identification of groups of sarcoma cells expressing tumour-specific markers [4]. These techniques play a pivotal role in the refinement of sarcoma diagnosis, which is currently based on tumour morphology, immunohistochemistry and clinic-pathological correlation [2].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Goldblum JR, Folpe AL, Weiss SW, Enzinger FM, Weiss SW. Enzinger and Weiss’s soft tissue tumors. 6th ed. Philadelphia: Saunders/Elsevier; 2014. xiv, 1155 p.
Marino-Enriquez A, Bovee JV. Molecular pathogenesis and diagnostic, prognostic and predictive molecular markers in sarcoma. Surg Pathol Clin. 2016;9(3):457–73.
Fletcher CD. The evolving classification of soft tissue tumours—an update based on the new 2013 WHO classification. Histopathology. 2014;64(1):2–11.
Thway K. Pathology of soft tissue sarcomas. Clin Oncol (R Coll Radiol). 2009;21(9):695–705.
Burningham Z, Hashibe M, Spector L, Schiffman JD. The epidemiology of sarcoma. Clin Sarcoma Res. 2012;2(1):14.
Ferrari A, Sultan I, Huang TT, Rodriguez-Galindo C, Shehadeh A, Meazza C, et al. Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database. Pediatr Blood Cancer. 2011;57(6):943–9.
Casali PG, Blay JY, ECECPo experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v198–203.
Alston RD, Rowan S, Eden TO, Moran A, Birch JM. Cancer incidence patterns by region and socioeconomic deprivation in teenagers and young adults in England. Br J Cancer. 2007;96(11):1760–6.
Howlader NNA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK. SEER cancer statistics review, 1975–2008. Bethesda: National Cancer Institute; 2011.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66.
Worch J, Matthay KK, Neuhaus J, Goldsby R, DuBois SG. Ethnic and racial differences in patients with Ewing sarcoma. Cancer. 2010;116(4):983–8.
Grier HE. The Ewing family of tumors. Ewing’s sarcoma and primitive neuroectodermal tumors. Pediatr Clin N Am. 1997;44(4):991–1004.
Guo W, Xu W, Huvos AG, Healey JH, Feng C. Comparative frequency of bone sarcomas among different racial groups. Chin Med J. 1999;112(12):1101–4.
Matushansky I, Hernando E, Socci ND, Mills JE, Matos TA, Edgar MA, et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest. 2007;117(11):3248–57.
Lin PP, Pandey MK, Jin F, Raymond AK, Akiyama H, Lozano G. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis. 2009;30(10):1789–95.
Genadry KC, Pietrobono S, Rota R, Linardic CM. Soft tissue sarcoma cancer stem cells: an overview. Front Oncol. 2018;8:475.
Danielson LS, Menendez S, Attolini CS, Guijarro MV, Bisogna M, Wei J, et al. A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy. Am J Pathol. 2010;177(2):908–17.
Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O’Connell JX, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet. 2002;359(9314):1301–7.
Hatley ME, Tang W, Garcia MR, Finkelstein D, Millay DP, Liu N, et al. A mouse model of rhabdomyosarcoma originating from the adipocyte lineage. Cancer Cell. 2012;22(4):536–46.
Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62(1):135–40.
Windham TC, Pisters PW. Retroperitoneal sarcomas. Cancer Control. 2005;12(1):36–43.
Hartley AL, Birch JM, Blair V, Kelsey AM, Harris M, Jones PH. Patterns of cancer in the families of children with soft tissue sarcoma. Cancer. 1993;72(3):923–30.
Li FP. Cancer families: human models of susceptibility to neoplasia--the Richard and Hinda Rosenthal Foundation Award lecture. Cancer Res. 1988;48(19):5381–6.
Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48(18):5358–62.
Zahm SH, Fraumeni JF Jr. The epidemiology of soft tissue sarcoma. Semin Oncol. 1997;24(5):504–14.
Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015;373(24):2336–46.
Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG. Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncol. 2016;17(9):1261–71.
Evans SC, Lozano G. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today. 1997;3(9):390–5.
Varley JM, McGown G, Thorncroft M, Santibanez-Koref MF, Kelsey AM, Tricker KJ, et al. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res. 1997;57(15):3245–52.
Ognjanovic S, Olivier M, Bergemann TL, Hainaut P. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer. 2012;118(5):1387–96.
DerKinderen DJ, Koten JW, Nagelkerke NJ, Tan KE, Beemer FA, Den Otter W. Non-ocular cancer in patients with hereditary retinoblastoma and their relatives. Int J Cancer. 1988;41(4):499–504.
Yu CL, Tucker MA, Abramson DH, Furukawa K, Seddon JM, Stovall M, et al. Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst. 2009;101(8):581–91.
Kleinerman RA, Stovall M, Tarone RE, Tucker MA. Radiotherapy and genetic susceptibility to cancer in a cohort of retinoblastoma patients. Ann Epidemiol. 2004;14(8):593.
Kleinerman RA, Schonfeld SJ, Tucker MA. Sarcomas in hereditary retinoblastoma. Clin Sarcoma Res. 2012;2(1):15.
Kleinerman RA, Tucker MA, Abramson DH, Seddon JM, Tarone RE, Fraumeni JF Jr. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst. 2007;99(1):24–31.
Colman SD, Williams CA, Wallace MR. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat Genet. 1995;11(1):90–2.
Brekke HR, Ribeiro FR, Kolberg M, Agesen TH, Lind GE, Eknaes M, et al. Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group. J Clin Oncol. 2010;28(9):1573–82.
Mertens F, Rydholm A, Bauer HF, Limon J, Nedoszytko B, Szadowska A, et al. Cytogenetic findings in malignant peripheral nerve sheath tumors. Int J Cancer. 1995;61(6):793–8.
Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57(10):2006–21.
Hizawa K, Iida M, Mibu R, Aoyagi K, Yao T, Fujishima M. Desmoid tumors in familial adenomatous polyposis/Gardner’s syndrome. J Clin Gastroenterol. 1997;25(1):334–7.
Bale AE. Variable expressivity of patched mutations in flies and humans. Am J Hum Genet. 1997;60(1):10–2.
Hahn H, Wojnowski L, Zimmer AM, Hall J, Miller G, Zimmer A. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med. 1998;4(5):619–22.
Gripp KW, Scott CI Jr, Nicholson L, McDonald-McGinn DM, Ozeran JD, Jones MC, et al. Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. Am J Med Genet. 2002;108(1):80–7.
Bovee JV, Hogendoorn PC. Molecular pathology of sarcomas: concepts and clinical implications. Virchows Arch. 2010;456(2):193–9.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
Antonescu CR, Chen HW, Zhang L, Sung YS, Panicek D, Agaram NP, et al. ZFP36-FOSB fusion defines a subset of epithelioid hemangioma with atypical features. Genes Chromosomes Cancer. 2014;53(11):951–9.
Behjati S, Tarpey PS, Sheldon H, Martincorena I, Van Loo P, Gundem G, et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat Genet. 2014;46(4):376–9.
Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22(18):3813–25.
Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224(3):334–43.
Suijker J, Baelde HJ, Roelofs H, Cleton-Jansen AM, Bovee JV. The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or −2 blocks osteoblast differentiation in vitro and in vivo. Oncotarget. 2015;6(17):14832–42.
Suijker J, Oosting J, Koornneef A, Struys EA, Salomons GS, Schaap FG, et al. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. Oncotarget. 2015;6(14):12505–19.
Killian JK, Kim SY, Miettinen M, Smith C, Merino M, Tsokos M, et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 2013;3(6):648–57.
Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, Cho YJ, et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell. 2010;18(4):316–28.
Lee RS, Stewart C, Carter SL, Ambrogio L, Cibulskis K, Sougnez C, et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest. 2012;122(8):2983–8.
Kadoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell. 2013;153(1):71–85.
Guillou L, Aurias A. Soft tissue sarcomas with complex genomic profiles. Virchows Arch. 2010;456(2):201–17.
Liau JY, Lee JC, Tsai JH, Yang CY, Liu TL, Ke ZL, Hsu HH, Jeng YM. Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas. Mod Pathol. 2015;28(12):1545–54.
Garsed DW, Marshall OJ, Corbin VD, Hsu A, Di Stefano L, Schroder J, et al. The architecture and evolution of cancer neochromosomes. Cancer Cell. 2014;26(5):653–67.
Savage SA, Mirabello L. Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma. 2011;2011:548151.
Broadhead ML, Clark JC, Myers DE, Dass CR, Choong PF. The molecular pathogenesis of osteosarcoma: a review. Sarcoma. 2011;2011:959248.
Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011;144(1):27–40.
Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E, et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 2014;7(1):104–12.
Dourmishev LA, Dourmishev AL, Palmeri D, Schwartz RA, Lukac DM. Molecular genetics of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol Mol Biol Rev. 2003;67(2):175–212, table of contents.
McClain KL, Leach CT, Jenson HB, Joshi VV, Pollock BH, Parmley RT, et al. Association of Epstein-Barr virus with leiomyosarcomas in young people with AIDS. N Engl J Med. 1995;332(1):12–8.
Dawlatly SL, Dramis A, Sumathi VP, Grimer RJ. Stewart-Treves syndrome and the use of positron emission tomographic scanning. Ann Vasc Surg. 2011;25(5):699 e1–3.
Shon W, Ida CM, Boland-Froemming JM, Rose PS, Folpe A. Cutaneous angiosarcoma arising in massive localized lymphedema of the morbidly obese: a report of five cases and review of the literature. J Cutan Pathol. 2011;38(7):560–4.
Davidson T, Westbury G, Harmer CL. Radiation-induced soft-tissue sarcoma. Br J Surg. 1986;73(4):308–9.
Karlsson P, Holmberg E, Samuelsson A, Johansson KA, Wallgren A. Soft tissue sarcoma after treatment for breast cancer—a Swedish population-based study. Eur J Cancer. 1998;34(13):2068–75.
Arlen M, Higinbotham NL, Huvos AG, Marcove RC, Miller T, Shah IC. Radiation-induced sarcoma of bone. Cancer. 1971;28(5):1087–99.
Pisters PW. Preoperative chemotherapy and split-course radiation therapy for patients with localized soft tissue sarcomas: home run, base hit, or strike out? J Clin Oncol. 2006;24(4):549–51.
Tucker MA, D’Angio GJ, Boice JD Jr, Strong LC, Li FP, Stovall M, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med. 1987;317(10):588–93.
Brady MS, Gaynor JJ, Brennan MF. Radiation-associated sarcoma of bone and soft tissue. Arch Surg. 1992;127(12):1379–85.
Billings SD, McKenney JK, Folpe AL, Hardacre MC, Weiss SW. Cutaneous angiosarcoma following breast-conserving surgery and radiation: an analysis of 27 cases. Am J Surg Pathol. 2004;28(6):781–8.
Falk H, Herbert J, Crowley S, Ishak KG, Thomas LB, Popper H, et al. Epidemiology of hepatic angiosarcoma in the United States: 1964-1974. Environ Health Perspect. 1981;41:107–13.
Kogevinas M, Ferro G, Saracci R, Andersen A, Biocca M, Coggon D, et al. Cancer mortality in an international cohort of workers exposed to styrene. IARC Sci Publ. 1993;127:289–300.
Zambon P, Ricci P, Bovo E, Casula A, Gattolin M, Fiore AR, et al. Sarcoma risk and dioxin emissions from incinerators and industrial plants: a population-based case-control study (Italy). Environ Health. 2007;6:19.
Pahwa P, McDuffie HH, Dosman JA, McLaughlin JR, Spinelli JJ, Robson D, et al. Hodgkin lymphoma, multiple myeloma, soft tissue sarcomas, insect repellents, and phenoxyherbicides. J Occup Environ Med. 2006;48(3):264–74.
Balarajan R, Acheson ED. Soft tissue sarcomas in agriculture and forestry workers. J Epidemiol Community Health. 1984;38(2):113–6.
Eriksson M, Hardell L, Adami HO. Exposure to dioxins as a risk factor for soft tissue sarcoma: a population-based case-control study. J Natl Cancer Inst. 1990;82(6):486–90.
Hardell L, Lindstrom G, van Bavel B, Fredrikson M, Liljegren G. Some aspects of the etiology of non-Hodgkin’s lymphoma. Environ Health Perspect. 1998;106(Suppl 2):679–81.
Rhodes MC, Bucher JR, Peckham JC, Kissling GE, Hejtmancik MR, Chhabra RS. Carcinogenesis studies of benzophenone in rats and mice. Food Chem Toxicol. 2007;45(5):843–51.
Piscitelli D, Ruggeri E, Fiore MG, Rossi R, Guerriero S. Undifferentiated high-grade pleomorphic sarcoma in a blind eye with a silicone prosthesis implant: a clinico-pathologic study. Orbit. 2011;30(4):192–4.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Kabir, W., Choong, P.F.M. (2021). The Epidemiology and Pathogenesis of Sarcoma. In: Choong, P.F.M. (eds) Sarcoma . Springer, Singapore. https://doi.org/10.1007/978-981-15-9414-4_2
Download citation
DOI: https://doi.org/10.1007/978-981-15-9414-4_2
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-9413-7
Online ISBN: 978-981-15-9414-4
eBook Packages: MedicineMedicine (R0)